Field Trip's new psychedelic molecule, FT-104, is showing similar efficacy to psychedelics like psilocybin -- but with shorter duration.
Field Trip's new psychedelic molecule, FT-104, is showing similar efficacy to psychedelics like psilocybin -- but with shorter duration.
Markets are tumbling. Where do you want to be positioned AFTER the selloff is over? Psychedelic stocks.
Entheon Biomedical has received conditional approval from the CSE to commence public trading.
MAPS' recent economic study revealed huge cost savings from MDMA-assisted therapy to treat PTSD. But that could be just the beginning of the savings.
MDMA-assisted psychotherapy for PTSD is estimated to produce cost savings of $103,200 per patient, over a 30-year treatment horizon.
As the new rally in psychedelic stocks progresses, these four companies are currently setting the pace.
Numinus announces its first psilocybin harvest and the appointment of a new Science Officer.
Field Trip Health opens a new clinic in Chicago, its 4th ketamine-assisted psychotherapy clinic.
An enormous Crisis. Huge treatment markets. Massive disruption potential. Welcome to the psychedelic drug industry.
The latest psychedelic drug company to commence public trading is Psyched Wellness.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now